Drug Discovery World

DECEMBER 22, 2023

Positive Phase I results for a new solid dose prescription cannabidiol (CBD) demonstrate the tolerability and bioavailability of the drug. Neuroscience drug discovery company Sapient Therapeutics successfully completed Part B of the Phase I trial comparing its CBD therapy SAP021 with Epidiolex.

Medicine 52

Medicine Bioavailability Clinical Development Trials 52

Pharmaceutical Technology

AUGUST 30, 2022

Under the deal, Zerion will handle the development of Dispersome formulations of marketed drugs. The finished product dosage form, clinical development and the final products’ marketing and sales across the globe will be handled by Insud. . All the clinical and other development expenses will be handled by Insud.

Development 130

Development Drugs Bioavailability Production 130

The Pharma Data

MARCH 8, 2021

Molnupiravir (EIDD-2801/MK-4482) is an investigational, orally-bioavailable form of a potent ribonucleoside analog that inhibits the replication of multiple RNA viruses including SARS-CoV-2, the causative agent of COVID-19. About Molnupiravir.

Trials 69

Trials In-Vivo Genotoxicity RNA 69

XTalks

MAY 23, 2024

XTALKS WEBINAR: Enhancing Efficiency in Early-Phase Oncology Trials: Strategies for Accelerating Data Flow Live and On-Demand: June 24, 2024, at 11am EDT (4pm BST/UK) Register for this webinar today to gain insights into how you can navigate and overcome data flow challenges in early-phase oncology clinical trials.

Life Science 72

Life Science Dermatology Drug Delivery Systems Medicine 72

pharmaphorum

NOVEMBER 9, 2022

for the purpose of advancing disease-modifying oral medicines for debilitating chronic neurodegenerative disorders, by enabling investigational new drugs (IND) studies. A pre-clinical pipeline of potential first-in-class brain-penetrant small molecule inhibitors of the mitochondrial permeability pore (mPTP) are to be developed.

In-Vitro 52

In-Vitro Bioavailability Medicine Clinical Trials 52

XTalks

APRIL 11, 2023

By avoiding the stomach entirely, there is increased bioavailability and more sustained relief from symptoms. ND0612 is currently in Phase III of clinical development and is supported by four years of safety data. Ambroxol is a cough medicine in the mucolytics family (thins and removes mucus from airways).

Bioavailability 98

Bioavailability Genetics Nurses Development 98

Delveinsight

JULY 30, 2020

The pharma players are evaluating their pipeline candidates in different stages of clinical development. A novel, brain penetrant, orally bioavailable and selective PPAR? Adrenoleukodystrophy Pipeline. Adrenoleukodystrophy pipeline therapies comprise Lenti D , leriglitazone , MGTA-456 , MD1003 , OP-101 , SOM1201 and others.

Hormones 52

Hormones Marketing Gene Trials 52